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DNA hypomethylation in rheumatoid arthritis synovial
fibroblasts
Abstract
OBJECTIVE: Rheumatoid arthritis synovial fibroblasts (RASFs) are phenotypically activated and
aggressive. We undertook this study to investigate whether the intrinsic activation of RASFs is due to
global genomic hypomethylation, an epigenetic modification. METHODS: Global genomic
hypomethylation was assessed by immunohistochemistry, flow cytometry, and L1 promoter bisulfite
sequencing. The levels of Dnmt1 were determined in synovial tissue and cultured SFs by Western
blotting before and after treatment with cytokines and growth factors. Normal SFs were treated for 3
months with a nontoxic dose of the DNA hypomethylation drug 5-azacytidine (5-azaC), and changes in
gene expression were revealed using complementary DNA arrays. The phenotypic changes were
confirmed by flow cytometry. RESULTS: In situ and in vitro, RASF DNA had fewer 5-methylcytosine
and methylated CG sites upstream of an L1 open-reading frame than did DNA of osteoarthritis SFs, and
proliferating RASFs were deficient in Dnmt1. Using 5-azaC, we reproduced the activated phenotype of
RASFs in normal SFs. One hundred eighty-six genes were up-regulated >2-fold by hypomethylation,
with enhanced protein expression. These included growth factors and receptors, extracellular matrix
proteins, adhesion molecules, and matrix-degrading enzymes. The hypomethylating milieu induced
irreversible phenotypic changes in normal SFs, which resembled those of the activated phenotype of
RASFs. CONCLUSION: DNA hypomethylation contributes to the chronicity of RA and could be
responsible for the limitation of current therapies.
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Abstract 
Background Rheumatoid arthritis synovial fibroblasts (RASF) are phenotypically activated 
and aggressive. We investigated whether RASF’s intrinsic activation is due to global genomic 
hypomethylation, an epigenetic modification.  
Methods Global genomic hypomethylation was assessed by immunohistochemistry, flow 
cytometry and LINE-1 promoter bisulfite sequencing. The levels of DNA-methyltransferase 1 
(DNMT1) was determined in synovial tissues and cultured synovial fibroblasts by Western 
blot, before and after treatment with cytokines and growth factors. Normal synovial 
fibroblasts (NSF) were treated for 3 months with a non-toxic dose of the DNA 
hypomethylation drug 5-azacytidine (5-AzaC) and changes in gene expression were revealed 
using cDNA arrays. The phenotypic changes were confirmed by flow cytometry.  
Results In situ and in vitro, RASF DNA has fewer 5-methylcytosine and methylated CG sites 
upstream of a LINE-1 open reading frame than does DNA of osteoarthritis synovial 
fibroblasts, and proliferating RASF are deficient in DNMT1. We reproduced the activated 
phenotype of RASF in NSF with 5-AzaC. 186 genes were more than two-fold up-regulated by 
hypomethylation, with enhanced protein expression. This included growth factors and 
receptors, extracellular matrix proteins, adhesion molecules, and matrix-degrading enzymes. 
The hypomethylating milieu induced irreversible phenotypic changes in NSF, which 
resembled that of the activated phenotype of RASF.  
Conclusion DNA hypomethylation contributes to the chronicity of rheumatoid arthritis and 
could be responsible for the limitation of current therapies. 
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Introduction 
Rheumatoid arthritis (RA), which affects approximately 1% of the population, is a chronic 
autoimmune disease involving progressive destruction of the affected joints. Pro-
inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF) are involved in its pathogenesis (1-3). Particularly anti-TNF 
therapies have been shown to provide substantial benefit to patients not only through the 
reduction of signs and symptoms of the disease, but also by the inhibition of joint destruction 
(1). However, treatments with current biologicals, including anti-TNF, anti-T cells and anti-
B cells therapies, are only successful at best in 60% of the treated patients and are still unable 
to cure the disease. A cytokine-independent pathway appears responsible for the ongoing joint 
destruction mediated by synovial fibroblasts (SF) (2). Since implantation of rheumatoid 
arthritis SF (RASF) with human cartilage into SCID mice causes invasion into the cartilage 
without the support of the cells of the human immune system, it has been proposed that the 
activated phenotype is an “intrinsic” property of these cells (3).  
 
SF, more than other types of fibroblasts, acquire phenotypic characteristics commonly 
associated with transformed cells (4). RASF show “spontaneous” activities, associated with 
aggressive behavior and different from the SF of patients with osteoarthritis (OASF) or 
normal SF (NSF). For example, RASF up-regulate proto-oncogenes (5), specific matrix 
degrading enzymes (6), adhesion molecules (7), and cytokines (8). These observations of an 
intrinsically activated cellular phenotype prompted us to search for epigenetic modifications.  
 
In somatic cells, DNMT1 is the predominant DNA methyltransferase (9, 10). Reduction of 
DNMT1 levels leads to hypomethylation, genomic instability, and tumorigenesis. Direct 
interaction between DNMT1 and proliferating cell nuclear antigen (PCNA) ensures that 
patterns of methylation are faithfully preserved in DNA synthesis (10). Moreover, repetitive 
sequences such as LINE-1, Alu, and satellite alpha repeats are silenced by methylation in 
normal cells, and can be used as markers of global hypomethylation (11). Our group and 
others (12, 13) reported a reactivation of the endogenous retroviral element LINE-1 in the RA 
synovial lining, and at sites of invasion. These reports suggest that global genomic 
hypomethylation plays a role in the pathogenesis of RA, and that genes normally silenced by 
methylation might contribute to the activated phenotype of RASF (12).  
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Here we show that DNA demethylation of normal synovial fibroblasts (NSF) induces a 
cellular phenotype resembling activated RASF. Genomic hypomethylation is a characteristic 
of RASF and is involved in the pathogenesis of RA.  
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Material and Methods 
 
Cell cultures. RASF and OASF were isolated from synovial tissues obtained during joint 
replacement surgery. Selected OA tissues showed no signs of inflammation or hyperplasia. 
NSF were isolated from a small joint biopsy of a trauma patient. The cells were cultured in 
DMEM including 10% FCS and employed between passages 5 and 6 (reagents from Life 
Technologies, Basel, Switzerland). The procedure was approved by a local ethical committee 
(University Hospital Zurich). The characteristics of the study patients were shown in Table 1. 
 
Immunohistochemistry for 5-methylcytosine (5-MeC). Formalin fixed, paraffin-embedded 
sections of synovial tissues were deparaffinised and treated at 80°C for 30 minutes with 
citrate buffer (pH 3.4). The tissue slides were incubated with 2N HCL for 2 hours at 37 C. 
After acid treatment, the slides were washed well with PBS / 0.05% Tween-20. To determine 
the methylation in the synovial tissues, mouse monoclonal antibodies against 5-MeC 
(Imgenex, San Diego, CA, USA) were used. Mouse IgG isotype (Dako, Glostrup, Denmark) 
served as negative controls. Double staining with vimentin (using murine anti-human 
monoclonal antibodies, clone V9, Dako) were used to stain synovial fibroblasts. The 
antibodies were incubated overnight at 4°C. Bound antibodies were detected by incubation 
with biotinylated goat anti-mouse IgG (Jackon Lab., Bar Arbor, Maine, USA) for 1 hour. The 
slides were incubated with ABC reagents for HRP (Vectastain, Vector Lab., Burlingame, CA, 
USA ). The methylcytosine modification and vimentin were visualised using DAB (Vector 
Lab.) and HistoGreen (Histoprime, Linaris, Wertheim-Bettingen, Germany)  respectively. 
ImageJ software (NIH) was used to analyse the mean intensity of nuclei in the patient tissues. 
We acquired three different microscopic field images per patient tissue. The color images 
were converted into 8 bit gray/white images. The threshold was adjusted for each image in 
order to specify only the nuclei. The mean of gray/white intensity of all nuclei in the image 
was obtained and compared. The numerical values given by software were converted to a 
mean intensity unit using the equation: Mean intensity = (1/mean of gray/white) x 100. 
 
Flow cytometry (FACS) for 5-MeC. The cells were fixed with 0.25% paraformaldehyde for 
10 minutes at 37°C and kept on ice for 10 minutes before addition of 88% methanol / 12% 
PBS for 10 minutes at -20°C. The nuclei were washed twice with PBST-BSA and treated with 
1N HCl for 40 minutes at 37°C. Neutralization of the acidic solution was performed by one 
wash step with 0.1 M borate buffer pH 8.5 and two wash steps with PBST/BSA. The nuclei 
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were incubated for 20 minutes at 37°C with a blocking solution that contains PBST/BSA 
supplemented with 10 % FCS. The nuclei were incubated with anti-5-MeC antibodies 
(Imgenex) for 1 hour at 37°C, washed twice with PBS and incubated with anti-mouse FITC 
antibodies for 30 minutes at 37°C (BD Biosciences, Heidelberg, Germany). Finally, the 
samples were stained also with propidium iodine (PI) before analysis by FACS (FACScalibur, 
BD Biosciences).  
 
Bisulphite sequencing for LINE-1 promoter. Genomic DNA was prepared from RASF and 
OASF using the QiAmp DNA blood Mini kit (Qiagen, Hombrechtikon, Switzerland). The 
DNA (1µg) was bisulphite modified using the EpiTect bisulphite kit (Qiagen). The modified 
DNA was eluted in 20 l of Tris Buffer (pH 8,5) and stored at -20°C. PCR amplification of 
bisulphite modified DNA (2 µl) was performed using Hot Start PCR and the AmpliTaq Gold 
polymerase (Applied Biosystems, Rotkreuz, Switzerland). Primers were designed for the CpG 
area upstream of LINE-1 promoter (X58075, -420 to -49 bp) forward 5-TTT ATT AGG GAG 
TGT TAG ATA GTG GG-3 and reverse 5-AAA CCC TCT AAA CCA AAT ATA AAA TAT 
AAT-3. The online MethPrimer software was used (http://www.urogene.org/methprimer/). 
The PCR purified fragment was cloned using the TOPO TA cloning kit according to 
manufacturer instructions (Invitrogen, Carlsbad, CA, USA). The positive clones were 
sequenced (Microsynth, Balgach, Switzerland). The data analysis was performed using the 
BiQ analyzer software (Max Plank Institut, Munich, Germany). 
 
Immunohistochemistry for LINE-1 proteins. LINE-1 ORF1p and ORF2p were detected by 
immunohistochemistry on paraffin-embedded sections of synovial tissues. Rabbit polyclonal 
antibodies against LINE-1 ORF1p and chicken polyclonal antibodies against LINE-1 ORF2p 
(obtained from G.G. Schumann, Paul-Ehrlich-Institut, Section PR2 / Retroelements, Langen, 
Germany), anti-rabbit or anti-chicken biotinylated antibodies, streptavidin conjugated to 
alkaline phosphatase (Jackson Lab.) were used and Fast Red Substrate (Vector Lab.) revealed 
the staining. Non-immune rabbit or chicken sera were used as a control for primary 
antibodies. 
 
Western blot for DNMT1 and PCNA. Tissue or cells were prepared by lyses in RIPA buffer 
(50 mM Tris HCL pH 8, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 
reagents from Sigma-Aldrich, Buchs, Switzerland). Proteins were separated in 10% SDS-
polycrylamide gel and transferred to nitrocellulose membranes. Membranes were blocked for 
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1 hour in 5% nonfat dry milk with 0.05% Tween-20 in TBS (pH 7.4) and were incubated 
overnight with antibodies against human DNMT1 (Abcam, Cambridge, United Kingdom) or 
PCNA (PC10, Imgenex). After incubation with goat HRP-conjugated anti-mouse IgG 
secondary antibodies (Jackson Lab.) in 5 % non-fat dry milk with 0.05% Tween-20 in TBS 
(pH 7.4), bound antibodies were visualised using ECL chemiluminescence (Amersham, 
Buckinghamshire, United Kingdom). Intensity of the bands were evaluated by densitometry 
(Alphaimager 2200, Witec AG, Littau, Switzerland).  
 
Treatment with TNFIL-1 or PDGF. RASF and OASF were passaged 48 hours and 
serum-starved (0,5% FCS) 24 hours before adding 10 ng/ml recombinant human TNF, 1 
ng/ml IL-1 or 10 ng/ml PDGF (R&D Systems, Minneapolis, MN, USA) (or medium alone) 
to the cell culture. The cells were kept in DMEM containing 10% FCS and collected after 24 
or 48 hours. 
 
Microarray of 5-Azacytidine induced gene expression. NSF (n=1) were treated with a low 
dose of 5-azacytidine (0,1 M/ml 5-AzaC for 3 months, with medium changed every 3 days 
over 2 passages)(Sigma-Aldrich) or left untreated (control group). The long incubation was 
used to have enough cell divisions and to mimic the chronic state of the disease. Total RNA 
was isolated with the RNeasy MiniPrep Kit (Qiagen) including treatment with RNase-free 
DNase. Double-stranded cDNA was synthesized from 5µg total RNA using the GeneChip 
One-cycle cDNA Synthesis Kit, including labeling with the One-cycle Target Labeling Assay 
(Invitrogen). The labeled cDNA was hybridized with the probe sets present on the Human 
Genome U133 Plus 2.0 Gene Expression Array (Affymetrix, Santa Clara, CA), using the 
Fluidics Station 450, according to standard protocols. The hybridization-picture was scanned 
with a GeneChip Scanner 3000 and further analyzed using the GCOS software. Data were 
normalized (measurements less than 0.01 were set to 0.01, and normalization per chip was set 
to 50th percentile) and analyzed with GeneSpring Microarray Analysis Software (Silicon 
Genetics, Redwood City, CA). Filters were set on 2-fold regulation, expression levels had to 
be >2.0, flags had to be present or marginal in at least one out of 2 compared samples. 
 
Flow cytometry. RASF and OASF were treated with a low dose of 5-AzaC (0,1 M/ml 5-
AzaC for 2 weeks, with medium changed each 3 days). The cells were detached using 
Accutase (Omnilab) and incubated with the following primary antibodies or isotype controls 
for 1 hour at 4°C in DMEM including 10% FCS: CD10, CD26, CD29, CD36, CD46, CD130 
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(murine monoclonal antibodies, BD Pharmingen), MMP-14 hinge region (rabbit polyclonal 
antibodies, Chemicon, Zug, Switzerland), transforming growth factor  receptor 2 (TGF-
R2), CK (murine polyclonal antibodies, Abnova, Heidelberg, Germany). Cathepsin K (CK) 
was measured in permeabilized cells (using DakoCytomation IntraStain). The cells were 
further incubated with secondary fluorescein-conjugated antibodies: goat anti-mouse IgG/IgM 
or rat anti-rabbit IgG (BD Pharmingen). The mean fluorescence intensity was determined by a 
FACScalibur.  
 
Gene analysis. The following online programs were used: Ensembl genome browser 
(http://www.ensembl.org/index.html), CpGplot (http://www.ebi.ac.uk/emboss/cpgplot/), 
Transcription Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess) and TFBS 
list (http://lgsun.grc.nia.nih.gov/geneindex/mm6/TFBS/list.html). 
 
Statistics. Differences between patient groups were evaluated using the Mann-Witney U-test, 
whereas changes in the same cell culture were evaluated using the Wilcoxon signed ranks test. 
Analysis of frequency was performed using Chi squared tests.  
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Results 
Global genomic hypomethylation in RA synovial tissues. To visualize global genomic 
methylation, paraffin-embedded synovial tissue sections from RA and OA patients were 
stained with anti-5-MeC monoclonal antibodies (Fig. 1). In RA, the vimentin positive 
synovial fibroblasts showed decreased stainings of cell nuclei in both lining and sublining, 
reflecting a generalized genomic hypomethylation (Fig.1A). Detailed image analysis of OA 
and RA nuclei in the synovial lining and sublining showed that RA nuclei are stained less 
densely in comparison to OA nuclei (Fig.1B). Thus, synovial cell nuclei were 13% less 
methylated in RA (range 10 to 20%), than in OA (Fig.1C, n = 6 each, p < 0.05).  
 
Global genomic hypomethylation in RASF and effects of cytokines and growth factors. 
To determine whether RASF are still hypomethylated in vitro, SF were isolated from tissues 
and cultured for five to six passages. In addition, we investigated the effect on DNA 
methylation of exposure to physiological concentrations of pro-inflammatory cytokines and 
growth factors. Cells were stimulated or left untreated, and harvested. Cell nuclei were stained 
with anti-5-MeC monoclonal antibodies (Fig. 2A) and propidium iodide (Fig. 2B), and 
analyzed by flow cytometry. The cell nuclei of untreated RASF, compared with untreated 
OASF, showed significantly less 5-MeC staining (Fig. 2A/C, n = 6, p<0.05). In RASF, 5-
MeC remained significantly reduced even in the presence of pro-inflammatory cytokines, 
TNF or IL-1 (n = 6, p<0.05). TNF significantly increased the 5-MeC content (p < 0.05 for 
both OASF and RASF), while IL-1 and PDGF had no effect. However, the relative deficiency 
of 5-MeC remained in RASF, when compared to OASF (p<0.05, n = 6 each). 
 
Cell cycle analysis. We determined the percentage of OASF and RASF cells in the G2/M 
phase in the different conditions, i.e. with or without the addition of cytokines or growth 
factors (Figs. 2B/D). The strongest increase occurred with TNF within 24 hours. However, 
no significant difference was detected between OASF and RASF in the different conditions (n 
= 6 each, p between 0.8 and 0.9).  
 
Expression of DNMT1 and PCNA and effects of cytokines and growth factors. We 
performed Western blots with specific monoclonal antibodies to search for a defect in the 
methylation pathway. Tissue and cell lysates were analyzed for the expression of DNMT1 and 
PCNA. In RA synovial tissues, compared with OA synovial tissues, the ratio DNMT1/PCNA 
was significantly lower (n = 6 each, p < 0.05) (Fig. 3A). In RA, an increased rate of cell 
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proliferation was associated with high levels of PCNA. In proliferating cells, it would be 
expected to find an increased expression of DNMT1; this was not the case in RA synovial 
tissues. The levels of DNMT1 were even lower in RA than in OA which showed low 
expression of PCNA and a low rate of proliferation. This observation suggested a deficient 
production or a decreased half-life of DNMT1 in the RA synovial tissue.  
In vitro, the ratio DNMT1/PCNA remained significantly lower in RASF, than in OASF (n = 
6, p<0.05) (Fig. 3B). We tested the effect of pro-inflammattory cytokines and growth factors 
on the expression of DNMT1 (Fig. 3C). In OASF, the ratio of DNMT1/PCNA is reduced 
upon TNF (p<0.05) and increased by IL-1 (p<0.05); this difference is in great part due to a 
strong increase of PCNA after TNF stimulation. Important to note is that in all conditions 
tested, the ratio of DNMT1/PCNA was significantly reduced in RASF (n = 6, p<0.05).   
 
Hypomethylated LINE-1 promoter in RASF. Because LINE-1 proteins (L1 ORF1p and 
ORF2p) are expressed in the RA synovial tissues (Fig. 4A), we thought to determine whether 
their expression is due to genomic hypomethylation. 18 CG sites of the LINE-1 promoter / 5’-
UTR (i.e., GenBank-Nr. X58075, 372bp between nucleotides -49 and -420) were analyzed for 
changes in methylation by bisulphite sequencing. Genomic DNA derived from RASF 
revealed significantly fewer methylated CpG sites upstream of the LINE-1 ORF1, in 
comparison with OA-SF (78 + 2% versus 85 + 3% CpG methylation, P < 0.05, n = 7 patients, 
and 20 clones analyzed for each diagnosis) (Fig. 4B). Furthermore, we found that the 
methylation of LINE-1 promoter in the isolated synovial fibroblasts significantly correlates 
with the expression of L1 ORF1p protein in the corresponding synovial tissue (Fig.4C). 
Fibroblasts derived from RA tissues with increased L1 ORF1p expression showed higher 
percentage of unmethylated  and missing CpGs  than the control fibroblasts derived from a 
OA tissue. 
 
Phenotype of hypomethylated NSF. To explore whether a hypomethylating milieu is 
responsible for the activated phenotype of RASF, we continuously treated NSF (n=1) for 
three months with a non-toxic dose of the DNA hypomethylator 5-AzaC, and analyzed the 
modification in gene expression using microarrays. 186 genes were more than two times up-
regulated during this condition. Many of these genes are implicated in RA, including 
interleukins, growth factors and their receptors, extracellular matrix proteins and enzymes, 
matrix degrading enzymes and inhibitors, adhesion molecules (Suppl. Table 1), protein 
kinases, transcription factors, components of Wnt, Ras and Rho-signaling pathways, and 
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apoptosis-related proteins (Suppl. Table 2). The induced genes were categorized according to 
the occurrence of CpG islands in their respective promoters, in exons 1, or in both. Fifty-two 
of these genes have no CpG islands. One hundred and thirty-four of them have CpG islands in 
their promoters and/or exons 1 (P < 0.001). Transcription factors (18/22, P < 0.005) and 
adhesion molecules (10/11, P < 0.01) showed more CpG islands in their promoters and/or 
exons 1. We chose nine genes, which were more than five times up-regulated, and measured 
their expression by flow cytometry in the presence and absence of 5-AzaC. 
 
Up-regulation of genes with CpG islands in their promoters. To confirm the 5-AzaC 
expression microarray, OASF and RASF cultures (n=6, each) were treated for two weeks with 
a non-toxic dose of 5-AzaC and the protein expression was analysed by FACS. Examples of 
genes with CpG islands in their promoters are CD10, CD29 and CD130. These gene products 
were significantly increased after two weeks of treatment with 5-AzaC (Fig. 5A). Moreover, 
these proteins are significantly more expressed on the cell surface of untreated RASF than on 
OASF.  
 
Up-regulation of genes with CpG islands in exon 1. Several genes that showed a greater 
than five-fold up-regulation of mRNA have no clear CpG island in their promoters. However, 
some of them have a CpG island in exon 1. Examples are CD26, matrix metalloproteinase-14 
(MMP-14) and transforming growth factor receptor 2 (TGF-R2) (Fig. 5B). The baseline 
levels of CD26 and MMP-14 mRNA were the same in OASF and RASF. In presence of 5-
AzaC, however, CD26 and MMP-14 mRNA levels increased significantly over baseline in 
both OASF and RASF. TGF-R2 has a CpG island in exon 1, and its promoter showed an 
accumulation of CpGs. In OASF, 5-AzaC increased the levels of expression significantly. 
However, in RASF, TGF-R2 expression on the cell surface was maximal in the absence and 
presence of 5-AzaC.  
 
Up-regulation of genes without CpG islands in their promoters. Several genes without 
CpG or increased frequency of CpGs up-regulate more than five-fold in the presence of 5-
AzaC, including CD36, CD46, cathepsin K (CK) (Fig. 5C). The basal expressions of CD36 
and CD46 on the cell surface were maximal in RASF, significantly higher than OASF. Both 
are up-regulated in OASF by 5-AzaC. The baseline levels of CK were the same in OASF and 
RASF, but its expression was up-regulated upon treatment with 5-AzaC.  
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Differences between OASF and RASF in the response to hypomethylation. In OASF, 
CD10, CD36 and CD46 showed significantly more increases in expression upon 5-AzaC (Fig. 
5d), in great part because in RASF their expressions were already maximal.  
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Discussion 
 
Here we report that genomic hypomethylation developed in situ is conserved in RASF in vitro 
even after more than five passages, and confirm that the expression of LINE-1 proteins in 
RASF is associated with a partially hypomethylated LINE-1 promoter. The degree of CG 
hypomethylation (78% methylation in RASF, versus 85% in OASF cells) in the LINE-1 
promoter is similar to the degree of hypomethylation in tumor cells (9).  
 
It is essential to understand more about the induction and maintenance of this global genomic 
hypomethylation. Pro-inflammatory cytokines such as TNF, IL-1 and IL-6 have multiple 
influences on the pathogenesis of RA. IL-1 and IL-6 (15) can affect genomic 
methylation. TNF, however, had not been associated with epigenetic changes so far. We 
observed that a physiological dose of TNF accelerated the cell cycle, within 24 hours of 
exposure even more than IL-1 or PDGF. In OASF, stimulation of cell proliferation was 
accompanied by increased DNA methylation. This is not the case in RASF and therefore the 
relative degree of DNA hypomethylation remained in RASF  treated with TNFor IL-1. As 
a consequence, it can be hypothesized that RASF become progressively more hypomethylated 
during inflammation. This results in further activation of genes in RASF. 
 
Previous reports have shown that deficiency of DNMT1 are associated with genomic 
hypomethylation (10, 16, 17). DNMT1 interacts with PCNA at the DNA replication fork, and 
this system is responsible that methylation marks are correctly transmitted to daughter cells. 
In RASF, however, the expression of DNMT1 appeared deficient, either in unstimulated cells 
or after exposition to pro-inflammatory cytokines. Thus, in RASF, a relative deficiency of 
DNMT1 during cell proliferation could result in the observed genomic hypomethylation . 
 
Our work raises the question whether the global genomic hypomethylation is accompanied, or 
followed by, specific promoter hypermethylation, as this is the case in various tumors (9). At 
least one example is reported in the literature, i.e. by silencing the death receptor 3 (18), 
which could, at least in part, explain the relative resistance to apoptosis reported for RASF in 
certain partients (2). 
 
In SF, the loss of methylation marks in daughter cells could cause an irreversible 
differentiation into an aggressive phenotype. Based on our observations, we hypothesized that 
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NSF continuously treated with DNMTs-inhibitor 5-AzaC will resemble RASF. Indeed, a large 
number of gene transcripts (73/186, 39%) found to be up-regulated upon 5-AzaC and detected 
in cDNA microarrays, were previously described to be involved in the pathogenesis of RA. It 
is known that DNA methylation silence genes with CpG island promoters. Therefore, we 
choose three genes in the list provided by the microarrays, which showed more than as five-
fold up-regulation of mRNA and the presence of CpG islands in their promoters, namely 
CD10, CD29 and CD130. We confirm that they were expressed on the cell surface of RASF 
more than on the surfaces of OASF, and that they were increased within two weeks of 
treatment with a low dose 5-AzaC. It is well established that RASF attach to cartilage through 
adhesion molecules, including CD29 and CD61 (1 and 3 integrins) (7, 19). Invasion of 
RASF into cartilage requires the availability of these two integrins (19, 20). CD10, a neutral 
endopeptidase, is highly expressed on RASF (21), and presumably plays a critical role in the 
local regulation of peptide levels in the joint. IL-6 signaling involves both a specific IL-6 
receptor (IL-6R) and a ubiquitous signal-transducing protein, CD130 (gp130), which is also 
utilized by oncostatin M. Both IL-6 and oncostastin M are involved in the pathogenesis of RA 
(8, 22, 23). 
 
We evaluated also the expression of genes that have no CpG island in their promoters, but do 
have a CpG island in exon 1, namely CD26, MMP-14 and TGF-R2. CD26 (dipeptidyl 
peptidase IV) was found to be highly expressed in RA synovial tissues (24) and in 
proliferating RASF (25). The destruction of cartilage and bone in RA is in large part mediated 
by MMPs (20). MMP-14 has a central role because it cleaves other pro-MMPs, and converts 
them into active forms. Inhibition of MMP-1 and/or MMP-14 both result in a significant 
reduction of cartilage invasion by RASF (26). Our results are in line with previous published 
data in pancreatic cancer cells showing that 5-AzaC also upregulates the expression of MMP-
14 and MMP-1 (27). Expression of TGF-R2 was already maximal on RASF, as proposed 
earlier (28). 
 
One fourth of genes (51/186, 27% in Suppl. Tables 1 and 2) that were up-regulated upon 
treatment with 5-AzaC in NSF contain no CpG island (e.g. CD36, CD46, CK, caspase-1 and 
IL-1R1). For example, CD36, abundantly expressed in RA synovial tissues, binds pro-
inflammatory oxidized low density lipoproteins (29) and thrombospondin-1 (30). CD46 is a 
C3b- binding protein, which could be involved in tissue damage of RA (31), whereas CK, a 
key enzyme in bone resorption, is highly expressed in RA synovial tissue, not only by 
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osteoclasts, but also by RASF (32). Caspase-1 (IL-1 converting enzyme), which activates 
IL-1 in the RA synovial tissue (33), is also up-regulated in NSF by 5-AzaC. IL-1 stimulates 
both the synthesis and the activity of MMPs involved in cartilage destruction (34). 
 
The proportion of gene products up-regulated in NSF upon 5-AzaC treatment, which are 
involved in intercellular processes and interactions with the extracellular matrix, and which 
have been described in RA synovial tissues and/or RASF was particularly high (52/73, 71% in 
Suppl. Table 1). This includes twenty-two interleukins, growth factors and their receptors, 
thirteen extracellular matrix proteins and related enzymes; ten matrix-degrading enzymes and 
their inhibitors; and four adhesion molecules. Most importantly, among them, cathepsins, 
MMPs, mannosidase 1, carbonic anydrases and ADAM12 are involved in joint destruction; 
and lysyl oxidase increased the crosslinking of mature collagen, an early step in cartilage 
destruction.  
 
Many of the gene products also up-regulated in NSF upon 5-AzaC treatment are involved in 
intracellular processes, and play a role in RA (20/94, 21% in Suppl. Table 2). They include 
four protein kinases, ten transcription factors, two proteins in the Wnt pathway, two proteins 
involved in the regulation of actin filaments and Rho signaling, and two regulators of 
apoptosis. Furthermore, transcription factors which increased upon 5-AzaC (18/22, 82% in 
Suppl. Table 2) have CpG islands in their promoters and/or exon 1 more often than other 
genes revealed by the cDNA arrays. Many of them may play a role in RA, including ELF-1, 
ATF2, which binds to activator protein-1 (AP-1), C/EBP, NFAT5, CREB/ATF, HIF-2 and 
STAT1. The sustained up-regulation of multiple signaling and transcription pathways in a 
hypomethylating milieu clearly could be responsible for the intrinsically activated phenotype 
of RASF. The cDNA arrays identified proteins that are implicated in the normal or 
pathological function of SF, including one recently reported as a potential autoantigen in RA, 
cartilage glycoprotein-39 (gp-39) (35).  
 
CD10, CD36 and CD46 were also more up-regualted upon 5-AzaC in OASF than in RASF. 
All other gene expressions tested were upregulated in OASF and RASF at same extent. 
Bisulphite sequencing of the CD10 CpG island, however, showed that it is hypomethylated 
even in NSF (data not shown). Therefore, the gene is regulated indirectly or by a methylation-
independent mechanism. Other investigators have reported similar effects of 5-AzaC on 
myeloid leukemia genes (36). CD46 and CD36 do not have a CpG island in their gene 
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promoter, most likely they are regulated by indirect mechanisms. Other 5-AzaC microarray 
studies have shown up-regulation of genes in the absence of CpG islands in their promoters 
(37). Thus, 5-AzaC can apparently influence the expression of certain genes by different 
mechanisms. For example, it can affect histone modifications, up-regulate transcription 
factors, transcriptional repressors and/or the expression of microRNAs expression (38, 39). 
We provided a list of transcription factors which could be candidates for future investigations 
(Suppl. Table 2).  
 
In summary, we have reported here reduced DNA 5-MeC in RA synovial tissues and in 
cultured RASF. Specifically, the promoter of a LINE-1 element was partially demethylated, 
confirming the global genomic hypomethylation in RASF. Moreover, our observations 
suggested a progressive loss of methylation marks. It can be hypothesized that: 1) the loss of 
methylation marks could be responsible for the intrinsically activated and aggressive 
phenotype of RASF and 2) tissue-specific transcription factors, which are not normally 
expressed in synovial tissues, are up-regulated in the disease and can be responsible for the 
activation of many genes involved in the pathogenesis of RA. Moreover, genomic 
hypomethylation could explain the increased expression of multiple receptors, adhesion 
molecules, and matrix-degrading enzymes, which play a role in RA and explain the enhanced 
response of RASF to pro-inflammatory cytokines, leading all together to joint destruction. 
Thus, the epigenetic modifications of RASF may be responsible, at least in part, for the fact 
that current therapies do not work in all patients and do not cure the disease yet.  
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 Figures 
 
 
 
  
 
A) Osteoarthritis (OA, left) and rheumatoid arthritis (RA, right) synovial tissues are stained with monoclonal antibodies against 
5-methylcytosine (brown) and vimentin (green).  
 
B) The RA synovial fibroblasts showed lower intensity of brown staining (5-methylcytosine), than the OA synovial fibroblasts. 
Representative intensity histograms obtained by imageJ software. 
 
C) RA synovial tissues are significantly less methylated than the OA synovial tissues, as reflected by the lower nuclear staining 
of 5-methylcytosine (p<0.05, n = 6 each, determined by  imageJ software analysis).  
Figure 1. Immunohistochemistry shows global genomic hypomethylation in rheumatoid arthritis synovial tissues.  
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 Figure 2. Flow cytometric analysis of cell nuclei confirmed 
genomic hypomethylation of rheumatoid arthritis synovial 
fibroblasts in vitro – effects of proinflammatory cytokines and 
growth factors.  
 
A) Nuclei of rheumatoid arthritis and osteoarthritis synovial fibroblasts 
(RASF and OASF) labeled with anti-5-methylcytosine (5-MeC)-FITC 
antibodies and evaluated by flow cytometry. Representative example 
of reduced 5-MeC in the nuclei of RASF (black), compared with 
OASF (white) (gray lines, IC: isotype control).  
B) Example of cell cycle analysis using propidium iodine (PI) showing 
distinct G1, S and G2/M phases, in unstimulated synovial fibroblasts 
or upon exposure for 24h to TNFa.  
C) Histograms of mean fluorescence intensity (MFI) of stainings with 
5-MeC. Unstimulated RASF showed a significant reduction in 5-MeC. 
The cells were treated with TNFa, IL-1β or PDGF. In all conditions 
tested – except PDGF -, the relative deficiency of 5-MeC remains 
significant in RASF, when compared to OASF (p<0.05, n = 6 each). 
D) The % of total cells in G2/M phase of cell cycle is shown in 
unstimulated and stimulated synovial fibroblasts (same experiment as 
in C). As expected, the proliferation increased upon stimulation, but no 
difference could be detected between OASF and RASF (means and 
standard deviations; * significantly p<0.05 increased compared to 
unstimulated control cells; NS = non significant).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22
  
 
 
  Figure 3. Relative deficiency of DNA-methyltransferase 1 
(DNMT1) in proliferating cells. 
 
A) In rheumatoid arthritis synovial tissues (RA), compared with 
osteoarthritis synovial tissues (OA), the level of DNMT1 is very 
representative examples of two patients with OA and two patients 
with RA, as revealed by Western blot). The ratio DNMT1 / PCNA 
(right) was significantly reduced in RA (n=5 each, p<0.05). 
B) The expression of DNMT1 was decreased also in RA synovial 
fibroblasts (RASF) in vitro, compared to OA synovial fibroblasts 
(OASF) (left, representative examples). The histogram (right) shows 
that the ratio of DNMT1/PCNA is significantly lower in RASF, than 
in OASF (n = 6 each, p<0.05).. 
C) Stimulation of cells with TNFa for 24 hours increased the 
expression of PCNA, but the levels of DNMT1 in RASF remained 
very low (left, representative examples of TNFa stimulated OASF 
and RASF). Important to note is that in all conditions tested 
(including IL-1b and PDGF), the ratio of DNMT1/PCNA remained 
significantly reduced in RASF (n = 6, p<0.05, means and standard 
deviations; * significantly p<0.05 increased compared to 
unstimulated control cells in B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
  
 
 
 
Figure 4. LINE-1 proteins and promoter hypomethylation in 
rheumatoid arthritis synovial fibroblasts (RASF). 
 
A) LINE-1 proteins (L1 ORF1p / p40 in fibroblasts at sites of 
cartilage destruction and L1 ORF2p / p150 in round-shaped cells at 
sites of bone destruction) are expressed in rheumatoid arthritis (RA) 
synovial tissues. 
B) The LINE-1 promoter (5’-UTR, 372bp containing 18 CpG sites) 
is hypomethylated in RASF (black bars), compared with OASF 
(white bars). Bisulphite sequencing was performed in 25 clones from 
seven RASF and seven OASF cultures. The results were analyzed 
using BiQ-Analyser software and expressed in terms of mean plus 
standard deviation. CpG sites, particularly at positions one and nine, 
are significantly hypomethylated, in addition to a significant overall 
hypomethylation. The p values refer to differences between OASF 
and RASF (Mann-Whitney U-test). C) Correlation of LINE-1 
promoter methylation in isolated synovial fibroblasts and L1 ORF1p 
protein expression in the corresponding synovial tissues in RA and 
OA. 
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Figure 5. Protein expression by flow cytometry of gene products 
up-regulated in an hypomethylating milieu in osteoarthritis (OA) 
and rheumatoid arthritis (RA) synovial fibroblasts.  
 
A-C) Confirmation of the data obtained by Affimetrix cDNA arrays 
for normal synovial fibroblasts continuously treated with 5-AzaC, 
inducing genomic hypomethylation. Box plots of mean fluorescence 
intensity. OASF n = 6 (white boxes) versus RASF n = 6 (gray 
boxes): * p < 0.05, ** p < 0.01, *** p < 0.001 (Mann-Whitney U-
test). Control (untreated) versus 5-AzaC: + p < 0.05, ++ p < 0.01, 
+++ p < 0.001 (Wilcoxon signed rank test). 
D) Percentages of increase from baseline in OASF (open bars) and 
RASF (black bars). Significant differences in gene expression (n = 6, 
p<0.05) between OASF and RASF in reaction to 5-AzaC were 
observed for CD10
 
 
 
 
 
 
 , CD36 and CD46.
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